National Product Launch to Include 24-oz and Convenient 4-oz Travel Size Spray Bottles
SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced an agreement with Sterifide Laboratories for the distribution of PURE's silver dihydrogen citrate (SDC)-based disinfectant as OneShot Plus(TM) DD, a new technology in Sterifide Laboratories' OneShot Plus product line. OneShot Plus DD eliminates MRSA and VRE in only 2 minutes.
Patrick Hurst, Vice President of Operations of Sterifide Laboratories, stated, "We live in a world where various types of organisms causing significant health problems have become resistant to previously effective disinfectants and antibiotics, and we are concerned about the growing threat of resistant pathogens like MRSA and VRE. Until recently, those pathogens were typically confined to hospitals and other closed environments but are now plaguing our communities."
Hurst continued, "That is why we welcomed the opportunity to partner with PURE Bioscience in order to add the SDC-based disinfectant as a powerful weapon against MRSA and VRE to our OneShot Plus line of products. We are first marketing OneShot Plus DD through direct-to-consumer channels, and we plan to launch our 24-oz spray and convenient 4-oz travel size nationwide by April along with the other products in our OneShot line. The marketing program targets both English and Spanish speaking consumers."
Michael L. Krall, President and CEO of PURE Bioscience, commented, "Sterifide will be uniquely positioned as it sells its SDC-based disinfectant through a new market channel. Sterifide's sales and marketing program should further increase awareness and acceptance of SDC as a truly revolutionary disinfectant."
OneShot Plus DD
OneShot Plus DD (currently completing registration in all 50 states) carries remarkable efficacy claims, including a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a 2-minute kill time on some resistant strains of bacteria including MRSA and VRE, a 10-minute kill time on fungi, a 30-second kill time on HIV Type I and 3-10-minute kill times on other pathogenic viruses. These claims distinguish the efficacy of OneShot Plus DD from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, OneShot Plus DD is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products. Each bottle of OneShot Plus DD features PURE's "Powered by SDC" logo.
About Sterifide Laboratories
Founded in 2006 to develop and commercialize specialty, eco-friendly and multipurpose cleaning products as well as disinfectants, Newport Beach, California-based Sterifide Laboratories focuses on launching new products to keep the environment cleaner and healthier. In addition to OneShot Plus DD, the current product line consists of a multi-purpose cleaner/degreaser and a soil remediation cleaner/degreaser. Sterifide Laboratories is dedicated to production of powerful and professional solutions for consumer, commercial and medical cleaning situations. For more information, please visit www.sterifidelabs.com.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Sterifide Laboratories Contact: Patrick Hurst, Vice President Operations Customer.firstname.lastname@example.org PURE Investor Contact: Paul G. Henning, Vice President Cameron Associates (212) 245-8800 email@example.com PURE Media Contact: Suzanne Matick Gutenberg Communications (831) 479-1888 Suzanne@gutenbergpr.com
|SOURCE PURE Bioscience|
Copyright©2009 PR Newswire.
All rights reserved